Tuesday 13 October 2026
Export PRTA’s income statement to Excel — free account
Prothena Corporation plc
PRTA Healthcare Biotechnology
Prothena Corporation plc’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 77.2%, EPS grew 84.6% and free cash flow grew 44.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.42
0.01
−0.12%
Follow PRTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.36 | 9.01 | 53.08 | 44.58 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.38) | 18.08 | (22.05) | (12.95) | |
P/B ratio |
1.78 | 1.67 | 1.83 | 1.78 | |
Price to Tangible BV |
1.78 | 1.67 | 1.83 | 1.78 | |
EV/Sales |
4.08 | 3.32 | 21.33 | 16.51 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.70) | (2.37) | (1.26) | (1.03) | |
EV/FCF |
(3.66) | (2.36) | (1.26) | (1.03) | |
Quick Ratio |
24.72 | 10.13 | 7.53 | 6.43 | |
Current Ratio |
25.05 | 10.43 | 7.72 | 6.61 | |
Net Debt/EBITDA |
14.28 | (10.64) | 13.22 | 8.42 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.16 | 0.14 | 0.02 | 0.02 | |
Operating CF/Net income |
1.35 | 0.88 | 1.08 | 1.11 | |
Capex/Depreciation |
(0.71) | 0.00 | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
871.09% | 24.72% | 69,457.14% | 1,198.26% | |
Selling, General and Administrative Expense of Revenue |
1,079.11% | 24.79% | 60,219.05% | 548.16% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
780.00% | 13.54% | 33,685.71% | 298.10% | |
Graham Net Nets |
0.54 | 0.58 | 0.52 | 0.54 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.48%) | (28.91%) | (47.54%) | (53.48%) | |
Free Cash Flow Yield |
(11.91%) | (15.61%) | (31.85%) | (35.83%) | |
Revenue per Share |
0.02 | 0.95 | 0.00 | 0.04 | |
Operating CF per Share |
(0.48) | 0.54 | (0.43) | (0.75) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.49) | 0.54 | (0.43) | (0.75) | |
Cash per Share |
5.53 | 6.13 | 5.71 | 6.15 | |
Shareholders Equity per Share |
5.50 | 5.82 | 5.21 | 5.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.50 | 5.82 | 5.21 | 5.48 | |
Free Cash Flow |
(25.70) | 28.88 | (23.31) | (40.57) | |
Working Capital |
280.36 | 306.68 | 274.35 | 288.54 | |
Capital Expenditures |
(0.65) | — | 0.00 | (0.01) | |
Net Current Asset Value |
276.33 | 301.92 | 268.86 | 282.34 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.65 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.07 | 10.16 | 6.82 | 10.42 | |
Average Assets |
350.82 | 422.62 | 436.96 | 473.94 | |
Average Common Equity |
305.61 | 375.15 | 383.70 | 414.68 |
Columns are period end dates